Fused heterocyclic compounds as ion channel modulators

Patent metadata

Field	Value
Publication number	US-8952007-B2
Application number	US-201314101740-A
Country	US
Kind code	B2
Filing date	Dec 10, 2013
Priority date	Oct 30, 2008
Publication date	Feb 10, 2015
Grant date	Feb 10, 2015

Abstract

The present invention relates to sodium channel inhibitors of Formula I:

in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

First claim

What is claimed is:

1. A compound selected from the group consisting of:
2-{2-oxo-6-[4-(trifluoromethoxy)phenyl]-3,4-dihydroquinolin-1(2H)-yl}acetamide;
2-[6-(2,4-difluorophenyl)-2-oxo-3,4-dihydroquinolin-1 (2H)-yl]acetamide;
2-{2-oxo-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinolin-1 (2H)-yl}acetamide;
2-{6-[4-chloro-3-(trifluoromethyl)phenyl]-2-oxo-3,4-dihydroquinolin-1(2H)-yl}acetamide;
tert-butyl 2-(6-(3-fluoro-4-(trifluoromethyl)phenyl)-2-oxo-3,4-dihydroquinolin-1(2H…

Assignees

• Gilead Sciences Inc

Inventors

• Abelman Matthew
• Chu Nancy
• Jiang Robert H
• Leung Kwan
• Zablocki Jeff

Classifications

• C07D471/04

  Chemistry & Metallurgy · mapped topic

• C07D401/06 Primary

  Chemistry & Metallurgy · mapped topic

• C07D215/227

  Chemistry & Metallurgy · mapped topic

• A61P9/04

  Human Necessities · mapped topic

• C07D413/06

  Chemistry & Metallurgy · mapped topic